Yazarlar : Longoni B, Mosca F.
Yayın : Curr Pharm Des.
Yayın Yılı : 2011
Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/21864271
Konu : Rejeneratif Tıp
Literatür İçeriği :
Abstract
Type 1 diabetes (T1D) is an autoimmune disease, leading to pancreatic β-cell destruction and loss of glycaemic control. Administration of exogenous insulin to diabetic patients prevents life-threatening metabolic derangement, but may fail to prevent other long-term complications, such as kidney failure or diabetic retinopathy. Islet transplantation is a low-risk surgical procedure, affording improved glucose homeostasis provided sufficient islets engraft in the liver. Here we review work on the use of stem cells to generate β-cells for islet transplantation, indicating the need for improved protocols for their derivation and full maturation. We also consider recent evidence indicating that adult stem/progenitor cells may affect islet transplantation by improving the viability of engrafted islets and controlling immune reactions to islet allo- and auto-antigens, extending stem-cell use in T1D beyond the regenerative approach.
Sunumlar | Videolar | Olgu Tartışması |